Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-MM5: Linvoseltamab monotherapy and linvoseltamab + carfilzomib versus standard-of-care regimens in relapsed/refractory multiple myeloma
jRCT2071260096Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab, carfilzomib, daratumumab, pomalidomide, bortezomib and 1 more in multiple myeloma (MM) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of treatment-emergent adverse events, Severity of treatment-emergent adverse events and 6 more. Started Oct 2026; status: recruiting.
02
Drugs
linvoseltamabcarfilzomibdaratumumabpomalidomidebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071260096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260096.